| Name | Title | Contact Details |
|---|
Decoding the dark matter of the human genome to uncover novel ways to treat disease Discover More
Twentyeight-Seven Therapeutics is a focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases.
Frontier Medicines is a pre-clinical stage biopharmaceutical company developing breakthrough medicines that redefine the course of debilitating diseases. According to the American Cancer Society, 1,762,000 new cancer cases and 607,000 deaths from cancer are expected to occur in the US in 2019. Our focus is developing treatments against important cancer-causing proteins that the biopharma industry hasn`t found a way to treat (or “drug”) with pharmaceutical interventions. After decades of research, this has become one of the most critical challenges in addressing human disease and advancing oncology therapy --central to the research at Frontier Medicines. Frontier Medicines is using chemoproteomics – an innovative approach to chemically interrogate proteins in living systems – to discover and pharmacologically target new binding pockets (or “hotspots”) on proteins, making them accessible to small-molecule drug discovery and development. The company`s proprietary chemoproteomics platform also integrates advanced computational approaches and machine learning to further accelerate the path to drug discovery.
Thoroughly validated, rapid, high-throughput multiplexed assays for protein biomarker discovery - high specificity & minimal sample volume requirements
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.